Pancreatic Cancer Research

ResearcherTokyo Medical UniversityActive in the last 2 years

Yuta Abe

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5840-8901; OpenAlex author ID A5101498190, A5122711030. Sources: OpenAlex.

Their work

Papers
26
Trials
0
Grants
0
Labs led
0
Collaborators
51
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: 2 papers · 2018: 1 paper · 2019: 2 papers · 2020: 3 papers · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 6 papers · 2025: 3 papers · 2026: 3 papers

Papers 26

  1. Impact of Sarcopenia During Induction Treatment in Patients With Unresectable Locally Advanced Pancreatic Cancer. Co-author DOI 10.1002/ags3.70078↗
  2. Preoperative CD44v6-positive extracellular vesicles as a prognostic biomarker in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00535-026-02343-2↗
  3. Postoperative risk stratification after upfront surgery for resectable pancreatic ductal adenocarcinoma in the S-1 adjuvant era. Co-author DOI 10.1016/j.pan.2026.05.008↗
  4. Clinical Impact of Neoadjuvant Therapy for Resectable Pancreatic Ductal Adenocarcinoma: A Single-Center Retrospective Study. Co-author DOI 10.1245/s10434-024-16851-z↗
  5. Perioperative 5-Fluorouracil and Portal Vein Infusion Chemotherapy Followed by Adjuvant S-1 for Resected Pancreatic Cancer (TOSPAC-02): A Phase 2 Clinical Tria… Co-author DOI 10.1245/s10434-025-17661-7↗
  6. Pancreatic Cancer Mimicking Relapse of Autoimmune Pancreatitis: Case Reports. Co-author DOI 10.70352/scrj.cr.25-0076↗
  7. Adjuvant 5-fluorouracil and portal vein infusion chemotherapy followed by gemcitabine for pancreatic cancer. Co-author DOI 10.1002/cam4.7459↗
  8. Molecular diagnosis for detecting KRAS mutation in peritoneal washing fluid of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-024-72569-8↗
  9. Prognosis prediction of PDAC via detection of O-glycan altered extracellular vesicles in perioperative sera. Co-author DOI 10.1111/cas.16341↗
  10. Efficacy and safety of neoadjuvant S-1-based chemoradiotherapy in resectable and borderline-resectable pancreatic cancer: a long-term follow-up study. Co-author DOI 10.1186/s12957-024-03609-w↗
  11. Efficacy and safety of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer Co-author DOI 10.21203/rs.3.rs-4671932/v1↗
  12. Next‑generation sequencing to identify genetic mutations in pancreatic cancer using intraoperative peritoneal washing fluid. Co-author DOI 10.3892/ol.2024.14272↗
  13. Long-term survival after surgical resection for bone metastasis from pancreatic cancer: A case report. Co-author DOI 10.1097/md.0000000000035856↗
  14. Peritoneal dissemination of pancreatic cancer caused by endoscopic ultrasound-guided fine needle aspiration: A case report and literature review. Co-author DOI 10.3748/wjg.v27.i3.294↗
  15. Usefulness of 18 F-fluorodeoxyglucose positron emission tomography/computed tomography for predicting the prognosis and treatment response of neoadjuvant thera… Co-author DOI 10.1002/cam4.3044↗
  16. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer. Co-author DOI 10.1111/cas.14425↗
  17. O-Glycan-Altered Extracellular Vesicles: A Specific Serum Marker Elevated in Pancreatic Cancer. Co-author DOI 10.3390/cancers12092469↗
  18. Efficacy and safety of preoperative 5-fluorouracil, cisplatin, and mitomycin C in combination with radiotherapy in patients with resectable and borderline rese… Co-author DOI 10.1186/s12957-019-1687-4↗
  19. Prognostic significance of the postoperative level and recovery rate of serum albumin in patients with curatively resected pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/mco.2019.1883↗
  20. KRAS mutations in cell-free DNA from preoperative and postoperative sera as a pancreatic cancer marker: a retrospective study. Co-author DOI 10.1038/bjc.2017.479↗
  21. Clinical predictive factors of long-term survival after curative resection of pancreatic cancer: a retrospective study. Co-author DOI 10.1002/cam4.1178↗
  22. Serum Metabolomic Profiles for Human Pancreatic Cancer Discrimination. Co-author DOI 10.3390/ijms18040767↗
  23. Two cases of pancreatic ductal adenocarcinoma with intrapancreatic metastasis. Co-author DOI 10.3748/wjg.v22.i41.9222↗
  24. Two Cases of Pathological Complete Response to Neoadjuvant Chemoradiation Therapy in Pancreatic Cancer. Co-author DOI 10.2302/kjm.2014-0014-cr↗
  25. Computer assisted surgery, preoperative planning and navigation for pancreatic cancer. Co-author DOI 10.1002/jhbp.84↗
  26. Prediction of a side effect and efficacy of adjuvant chemotherapy with gemcitabine for post operative patient of pancreatic cancer by a genetic polymorphism an… Co-author DOI 10.5754/hge11729↗

Closest collaborators

The 25 strongest of 51 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Minoru Kitago · 24 shared papers, 2014–2026 · strength 3.65
  2. Yutaka Nakano · 19 shared papers, 2017–2026 · strength 3.19
  3. Shutaro Hori · 16 shared papers, 2019–2026 · strength 2.88
  4. Yuko Kitagawa · 18 shared papers, 2014–2026 · strength 2.34
  5. Masayuki Tanaka · 11 shared papers, 2021–2026 · strength 2.28
  6. Yohei Masugi · 14 shared papers, 2015–2026 · strength 1.99
  7. Gaku Shimane · 5 shared papers, 2024–2026 · strength 1.05
  8. Yutaka Endo · 8 shared papers, 2018–2025 · strength 1.01
  9. Yuko Kitagawa · 5 shared papers, 2024–2025 · strength 1.01
  10. Sho Uemura · 4 shared papers, 2024–2026 · strength 0.95
  11. Koichi Aiura · 6 shared papers, 2015–2025 · strength 0.78
  12. Yosuke Uematsu · 2 shared papers, 2025–2026 · strength 0.48
  13. Yutaka Takigawa · 2 shared papers, 2024–2025 · strength 0.40
  14. Junichi Matsui · 2 shared papers, 2024–2025 · strength 0.40
  15. Hiroshi Nishihara · 2 shared papers, 2024 · strength 0.37
  16. Eisuke Iwasaki · 2 shared papers, 2021–2025 · strength 0.34
  17. Hideaki Kojima · 2 shared papers, 2021–2025 · strength 0.34
  18. Satoru Matsuda · 1 shared paper, 2026 · strength 0.30
  19. Kohei Mishima · 1 shared paper, 2026 · strength 0.30
  20. Michiie Sakamoto · 4 shared papers, 2015–2021 · strength 0.28
  21. Yasuaki Kabe · 2 shared papers, 2020–2024 · strength 0.26
  22. Takahiro Yokose · 3 shared papers, 2020 · strength 0.25
  23. Sojun Hoshimoto · 1 shared paper, 2025 · strength 0.22
  24. Yasunori Sato · 1 shared paper, 2024 · strength 0.18
  25. Minoru Tanabe · 1 shared paper, 2024 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.